fermin Gonzalez

Rheumatologist !

[Antoni Chan MD (Prof) @synovialjoints]

Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.

SUA <300 μmol/L at Week 36:
63.8% vs 40.7% (p<0.0001)

A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile

Abstr LB0008 @RheumNow #EULAR2026

[Rheumatology update @aabdogafar]

#EULAR2026 Sjogren disease and lymphoma

[TheDaoIndex @KDAO2011]

#EULAR2026 Imaging Recc on SpA summary: 1. MRI preferred for diagnosis, monitoring of axSpA 2. US/MRI for non axial disease diagnosis and monitoring
Note: Low dose CT can be used as a substitute imaging modality.

Radiographs may not be sensitive enough to detect changes

[Lupus Hub @lupus_hub]

CONGRESS | #EULAR2026 | PRESENTATION

Richard Furie presents phase II JASMINE-SLE data evaluating nipocalimab, the first FcRn blocker studied in #SLE, in patients with active disease despite standard therapy (N = 228).

• Primary endpoint was met with nipocalimab 15 mg/kg IV Q2W vs PBO at Week 24 using the prespecified 2-sided alpha of 0.10 (SRI-4, 53.5% vs 46.7%; p = 0.081), but was not met with nipocalimab 5 mg/kg.
• At Week 52, SRI-4 was 53.6% with nipocalimab 15 mg/kg vs 39.7% with PBO (OR, 2.1; p = 0.020); LLDAS was 37.5% vs 20.5% (OR, 2.5; p = 0.013).
• In the aAb-high subgroup, responses were greater with nipocalimab 15 mg/kg vs PBO for SRI-4 (75.8% vs 11.1%) and LLDAS (53.5% vs 11.1%).
• Nipocalimab reduced total IgG, CIC, and anti-dsDNA levels at Week 52; C3 levels increased with nipocalimab 15 mg/kg.
• Serious AEs occurred in 7.8% with nipocalimab 5 mg/kg, 13.2% with nipocalimab 15 mg/kg, and 8.0% with PBO; serious infections occurred in 5.2%, 3.9%, and 4.0%, respectively. No new safety signals were observed.

These results support proof of concept for FcRn blockade with nipocalimab in SLE.

Follow our live feed for more updates: https://t.co/WXrVHDpHZI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#RheumTwitter #rheumatology #MedNews #MedEd #MedicalCongress #lupus @NorthwellHealth

[Rheumatology update @aabdogafar]

Sjogren disease

[Tsvetoslav Georgiev @GeorgievMD]

A notable shift in the new EULAR recommendations: imaging SpA is no longer just diagnostic.
MRI and ultrasound can help monitor activity, predict outcomes and guide treatment in SpA. #Rheumatology #EULAR2026

[fermin Gonzalez @fergonleon]

@mariaj_morenom @SEReumatologia @SMurcianaReuma Hay que ser miembro de la sociedad para poder ver los review ?

[Lupus Forum @TheLupusForum]

Nipocalimab 15 mg/kg IV Q2W treatment led to significant improvement over placebo in SRI-4 composite response at Week 24 and improved SRI-4 composite and LLDAS responses at Week 52.#EULAR2026

[NEJM @NEJM]

Original Article: Obexelimab for the Treatment of IgG4-Related Disease (phase 3 INDIGO trial results) https://t.co/UP3IT4HLMN

Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease https://t.co/Km4LndkI5z

#EULAR2026 | @eular_org

[Luis Caminal @caminalm]

Evaluation and treatment of pericardial disease in immune-mediated inflammatory diseases https://t.co/F0LbjFxcDX

[Dr Gurdeep S Dulay @gurdeep_dulay]

ASAS-SPARTAN #AxSpA classification criteria 2025

⚠️ MRI needs to have inflammatory PLUS structural lesions

#EULAR2026 @Official_ASAS #sacroilitis #IBD #Uveitis #enthesitis

[fermin Gonzalez @fergonleon]

@INERsticio @karlita_chacon_ @jorroser Thanks for sharing but article isn’t free access !

[TheDaoIndex @KDAO2011]

#EULAR2026
PMR/GCA reccs:
1. Refer to a specialist with expertise
2. For GCA- start steroids without delay
3. PMR pred dose 15-25 mg/d taper to 10 mg/d in 1 year (for major relapse treat like new onset, for minor relapse, increase to last effective dose

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2026: Treating PH in CTD (Allanore)

Novel disease-modifying drug → sotatercept (TGF-β/activin pathway), can reverse pulmonary vascular remodeling.
Unlike idiopathic #PAH, CTD-PAH has an autoimmune component → treat the disease + the pulmonary vasculature.

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

🦋 #EULAR2026: New Insights into #SLE Therapy
(Bertsias)

Withdraw GC first in sustained remission; consider IS/biologic withdrawal after ≥3 yrs.
Safest GC withdrawal when 3 factors combine: slow taper (6m) + good HCQ adherence + remission (DORIS/LLDAS)

@ElvisHysa

[Ravi Kumar @RheumattDoc]

🧬 Obexelimab: A New Way to Control B Cells

Unlike rituximab, which removes B cells, obexelimab functionally silences them by co-engaging CD19 and the inhibitory receptor FcγRIIB (CD32B).

🔹 Inhibits B-cell activation
🔹 Reduces plasmablast formation
🔹 Decreases antibody production
🔹 Suppresses inflammatory cytokines
🔹 Minimal B-cell depletion

Obexelimab turns B cells “OFF” rather than wiping them out, potentially preserving immune function while controlling autoimmune disease.

#RheumattDoc #MedTwitter #RheumTwitter #Medicine #rheumatology @docakx @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1

[mariajosem @mariaj_morenom]

Mira q nos gustan estas tablas con colores. No me canso de verlas. Gracias por compartir #EULAR2026 @GRESSER_Espa @SEReumatologia @SMurcianaReuma

[Ritasman Baisya @RitasmanB]

👉👉SLEDAS - A single tool in SLE can measure disease activity , flare, meaningful improvement and low disease activity.

👉👉Easy to use, time saving , more specific than SLEDAI.
@EULAR2026
Poster

[Lupus Forum @TheLupusForum]

⭐ Chair's Pick
12:50 - 13:00 BST
Late Breaking Abstracts, LB0006: Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
👤Liying Peng (Beijing, China)

[Lupus Forum @TheLupusForum]

Add-on sirolimus significantly improved clinical and serological outcomes in patients with active SLE in a multicentre, double-blind, placebo-controlled trial, with a comparable safety profile and no unexpected safety signals.#EULAR2026